Menu
Search
|

Menu

Close
X

Benitec Biopharma Ltd BNTC.OQ (NASDAQ Stock Exchange Capital Market)

3.34 USD
-0.01 (-0.30%)
As of 2:29 AM IST
chart
Previous Close 3.35
Open 3.34
Volume 430
3m Avg Volume 10,674
Today’s High 3.35
Today’s Low 3.32
52 Week High 5.48
52 Week Low 1.85
Shares Outstanding (mil) --
Market Capitalization (mil) --
Forward P/E --
Dividend (Yield %) -- ( -- )

LATEST NEWS

ADVERTISEMENT

RECOMMENDATION

No Data Available
Sell Hold Buy

KEY STATS

Revenue
No Data Available
FY
-
FY
-
FY
-
FY
-
EPS
No Data Available
FY
-
FY
-
FY
-
FY
-

KEY RATIOS

Price to Earnings (TTM)
vs sector
--
32.90
Price to Sales (TTM)
vs sector
--
5.77
Price to Book (MRQ)
vs sector
--
5.41
Price to Cash Flow (TTM)
vs sector
--
23.42
Total Debt to Equity (MRQ)
vs sector
--
16.52
LT Debt to Equity (MRQ)
vs sector
--
12.22
Return on Investment (TTM)
vs sector
--
14.43
Return on Equity (TTM)
vs sector
--
16.13

EXECUTIVE LEADERSHIP

Jerel Banks
Non-Executive Chairman of the Board, Since 2017
Salary: --
Bonus: --
Gregory West
Chief Executive Officer, Company Secretary, Since 2016
Salary: $152,333.00
Bonus: --
Bryan Dulhunty
Chief Financial Officer, Since 2016
Salary: --
Bonus: --
Michael Graham
Chief Scientific Officer, Since 2012
Salary: --
Bonus: --
Kevin Buchi
Director, Since 2013
Salary: --
Bonus: --

COMPANY PROFILE

Sector: Healthcare
Industry: Biotechnology & Medical Research
Address:

SE 1201 99 Mount St
NORTH SYDNEY   NSW   2060

Phone: +612.95556986

Benitec Biopharma Limited is a biotechnology company. The Company is engaged in progressing programs through the clinic; the commercialization of its Intellectual Property (IP); development of its therapeutic pipeline and pre-clinical programs, and funding, and protecting and building the IP estate. Its In-house product candidates include TT-034, BB-HB-331, BB-AMD-211 and ddRNAi therapeutic. It is focused on commercialization by licensing and partnering of patents and licenses in biotechnology, in functional genomics, with applications in biomedical research and human therapeutics. It has a pipeline of in-house and partnered therapeutic programs based on its patented gene-silencing technology, deoxyribonucleic acid (DNA)-directed ribonucleic acid interference (ddRNAi). The Company is engaged in developing treatments for chronic human conditions, such as hepatitis B, wet age-related macular degeneration (AMD), and oculopharyngeal muscular dystrophy (OPMD) based on this technology.

SPONSORED STORIES